Helus Pharma

HELP · Nasdaq · Canada

Share price · HELP

$6.89-4.78 (-40.96%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.2M (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HELP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-13.5%
  2. 2 Nov 2026-16.9%

    Nothing announced by HELP that day or the session before.

  3. 9 Sep 2026+10.4%
  4. 12 Aug 2026+13.9%
  5. 10 Aug 2026-13.8%

    Nothing announced by HELP that day or the session before.

  6. 5 Aug 2026+13.5%

    Nothing announced by HELP that day or the session before.

  7. 4 Aug 2026+15.1%
  8. 21 Jul 2026+13.9%
  9. 16 Jul 2026+8.1%
  10. 25 Jun 2026+18.3%

Share of unusual movement by asset

For each asset, the share of HELP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Deupsilocin
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—49%
Sessions with no dated event—50%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
5-HT2A receptorSmall molecule
Major Depressive Disorder

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026Topline resultDeupsilocinPhase 3 APPROACH (HLP003) topline: primary and key secondary endpoints met

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2————report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$39M$94M$20M-$73M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$24M$154M$14M-$51M operating cash flowreport ↗
2023-FY—$19M$12M$8.9M-$36M operating cash flowreport ↗
2022-FY$0$14M$43M$13M-$36M operating cash flowreport ↗
2021-FY$0.7M$2.5M$51M$6.1M-$14M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($9.7M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30Glavine Paul · director, Chief Growth OfficerAward / grant248,000——Form 4
2026-09-30So Eric H. L. · directorAward / grant248,000——Form 4
2026-09-29Cavers Greg · Chief Financial OfficerOpen-market purchase3,000$12.91$39KForm 4
2026-09-21Halstead Michael · Chief Executive OfficerOpen-market purchase100,000$13.47$1.3MForm 4
2026-09-08So Eric H. L. · director, Executive ChairOpen-market purchase100,000$12.39$1.2MForm 4
2026-09-08Glavine Paul · Chief Growth OfficerOpen-market purchase100,000$12.47$1.2MForm 4
2026-09-08Glavine Paul · Chief Growth OfficerOpen-market purchase100,000$12.47$1.2MForm 4
2026-09-04So Eric H. L. · director, Executive ChairOpen-market purchase100,000$12.09$1.2MForm 4